Leerink Partners Downgrades Alnylam Pharmaceuticals (ALNY) to Market Perform

Alnylam Pharmaceuticals (ALNY) PT Cut to $77 at Chardan

Chardan Capital Markets analyst Madhu Kumar cut the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $77.00 (from $115.00) after the company announced the discontinuation of the development of revusiran, a RNAi drug
which was in phase III trials targeting transthyretin (TTR), for the treatment of TTR familial amyloid... More

Alnylam (ALNY) PT Cut to $137 at Needham & Company; Long-Term Investors Should Buy Weakness

Needham & Company analyst Alan Carr cut his price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $137.00 (from $152.00) after the company reported last night that the revusiran program has been terminated. An ad hoc review of unblinded Phase 3 ENDEAVOR trial data led the DMC... More

Credit Suisse Cuts Alnylam (ALNY) PT to $50, Keeps 'Outperform'

Credit Suisse analyst Alethia Young cut her price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $50.00 (from $145.00) but maintained an Outperform after the company announced termination of revusiran.

Young commented, "Lowering TP to $50/sh due to concerns about broader implications to the... More

Alnylam (ALNY) PT Cut to $58 at Jefferies

Jefferies analyst Gena Wang lowered her price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $58.00 (from $86.00) but maintained a Buy rating after the company announced termination of revusiran Ph3 due to mortality imbalance.

Wang commented, "Following recent discontinuation of ALN-AAT, ALNY announced termination of... More

BMO Capital Upgrades Ionis Pharmaceuticals (IONS) to Outperform; To Benefit form Alnylam Failure

BMO Capital upgraded Ionis Pharmaceuticals (NASDAQ: IONS) from Market Perform to Outperform with a price target of $48.00 (from $42.00), saying the company could benefit from Alnylam (NASDAQ: ALNY) discontinuation of the Revusiran program fter observing an imbalance of... More

Medicines Co. (MDCO) Sells-Off with Alnylam (ALNY) Despite Providing Update

Medicines Co. (NASDAQ: MDCO) is down 9.1% after-hours after Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced that upon the recommendation of the ENDEAVOUR Phase 3 study Data Monitoring Committee (DMC) to suspend dosing, the Company has decided to discontinue development of revusiran, an... More

Alnylam Pharma (ALNY) to Discontinue Development of Revusiran; Decision Will Not Affect Patisiran

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced that upon the recommendation of the ENDEAVOUR Phase 3 study Data Monitoring Committee (DMC) to suspend dosing, the Company has decided to discontinue development of revusiran, an investigational RNA interference (RNAi) therapeutic that was being developed for the treatment of hereditary ATTR amyloidosis with cardiomyopathy (hATTR-CM). This... More